Composition with magnolia and phellodendron amurense

JP2024160292AInactive Publication Date: 2024-11-13NUTRAMAX LABORATORIES INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024129938
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-08-31
Filing Date
2024-08-06
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 2024160292000001_ABST
    Figure 2024160292000001_ABST
Patent Text Reader

Abstract

To provide a natural product composition that has anxiolytic properties.SOLUTION: An anxiolytic composition includes a synergistic combination of one or more of an extract of magnolia, an extract of Phellodendron amurense, an L-theanine, a whey protein composition, and / or an s-adenosylmethionine (SAMe).SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Related Applications

[0001] This application claims priority to and incorporates by reference U.S. Provisional Patent Application No. 62 / 212,080, filed August 31, 2015. [Technical field]

[0002] The present invention generally relates to anxiolytic compositions containing magnolia, phellodendron, theanine, whey protein and / or S-adenosylmethionine. [Background technology]

[0003] Anxiety, fear and stress play a large role and contribute in some way to many behavioral disorders in humans and non-human animals. For example, in dogs and cats, storm phobia, noise phobia, social avoidance, fear-related aggression, threat-related disorders and submissive urination are obvious anxiety factors, but even problems such as urine marking, territorial aggression and resource guarding are amplified by fear and anxiety. In the United States, an estimated 23 million dogs suffer from fear and anxiety disorders, resulting in $1 billion in costs in treatment and property damage. Approximately 40% or more of dogs that are referred to shelters are abandoned due to behavioral problems, and 14% of cats are abandoned due to behavioral problems. In pet cats, behavioral problems remain the most common cause of euthanasia. A recent survey of pet owners found that 41% of dog owners reported that their dog exhibited anxiety at times, and 29% of current dog owners had anxiety problems. The most common concerns reported by these owners were noise phobia (17%), separation anxiety (13%) and generalized anxiety (5%).

[0004] Anxiety in horses is also a common problem in the horse industry, contributing to behavioral problems, training issues, and performance loss. In some cases, elevated anxiety levels can lead to health-related problems such as stomach ulcers, and some studies have shown that it affects many horses. In horses, anxiety can manifest not only in the form of stomach ulcers, but also behaviorally in the form of sudden galloping, jumping, panicked behavior, difficulty getting into the carriage, side-walking, refusal to enter or leave the stall, scratching the ground with hooves, and biting. In dogs, the most common risk factors for anxiety disorders are acquired in animal shelters and many foster homes, with up to 68.3% of shelter dogs thought to have some form of anxiety disorder. One previous study of behavioral diagnoses has shown that breed predilections are possible in Dalmatians, English Springer Spaniels, German Shepherds, and crossbreeds. Other studies have suggested that Cocker Spaniels, Schnauzers and Dachshunds may be at risk for separation anxiety. The incidence of anxiety disorders increases with age, primarily due to cognitive impairment, with a 22.5% incidence in dogs under three years of age and a 36.5% incidence in dogs over eight years of age.

[0005] Fear is an emotional response to the presence of a concrete stimulus (such as an object, a noise, or an individual human) that a pet perceives as threatening or dangerous. In contrast, anxiety is a reaction of concern or discomfort to an anticipated danger or threat. In other words, anxiety occurs in the absence of a identifiable stimulus, whereas for fear, the stimulus is usually identifiable. Anxiety and the associated psychological stress do not become pathological in the short term, but if stress and anxiety become chronic, it can impair the health, comfort and longevity of a pet. Thus, to ensure optimal health and comfort for all pets, veterinarians consider anxiety as another possible pathological condition in pets. In extreme cases, phobias are intense, excessive, abnormal fear responses that develop in the absence of a real threat or that develop independently of the need to address an actual threat. Fear is a normal adaptive response, whereas phobias are abnormal, maladaptive and generally disruptive to normal functioning. Anxiety is a mild response that is often overlooked or misunderstood, but can have a meaningful impact on a pet's daily well-being.

[0006] In dogs, clinical signs of fear and anxiety include hypervigilance, elimination, destructiveness, excessive vocalization, excessive salivation, panting, hiding, trembling and flight behavior. In cats, chronic anxiety and fear can also lead to secondary behavioral problems such as excessive grooming, spraying and inter-cat aggression, predisposing to health problems due to the toll on the cat's immune system. Since many of the clinical signs of fear and anxiety are harmful and distressing to both pet and owner, it is easy to understand why owners seek advice for such disorders. Not coincidentally, the most common risk factors for relinquishing animals to shelters, and for euthanasia in both dogs and cats, include house-soiling (inappropriate elimination), destructiveness, aggression and excessively abnormal behavior, all of which are potential clinical signs of anxiety.

[0007] Anxiety disorders rarely occur alone, but often occur in combination. Thunderstorm phobia and noise phobia do not necessarily occur together, but thunderstorm phobia, noise phobia, and separation anxiety occur more often than not together than alone. This evidence suggests that the exact cause of pet anxiety is difficult to determine, and that multiple conditions may occur in the same pet.

[0008] Although the "triggers" and onset of behavioral disorders are different in humans, anxiety, fear, and stress are predisposing factors for the disorder in humans. In an attempt to alleviate behavioral disorders in humans and non-human animals, certain synthetic drugs have been developed. Examples include clomipramine hydrochloride, fluoxetine hydrochloride, benzodiazepines, and acepromazine maleate, which are all pharmaceutical compositions that have been used in an attempt to alleviate anxiety in humans and / or non-human animals. Although these drugs provide some relief from anxiety, a major side effect is sedation, which can cause drowsiness in humans and non-human animals. Furthermore, many of these drugs are synthetic compositions that humans are hesitant to ingest and may be hesitant to administer to pets.

[0009] The biochemistry of anxiety is extremely complex and largely incomprehensible. Research suggests that nearly every type of neurotransmitter and hormone, from serotonin, gamma-aminobutyric acid (GABA), glutamate, and dopamine to cortisol, adrenaline, and thyroid hormones, tends to play some role in anxiety. In many ways, anxiety is simply the brain's biochemical response to stress. When something causes a change in the delicate chemical balance in the brain, anxiety is often the result.

[0010] Therefore, the ideal management of anxiety should be multi-modal, i.e., comprised of one or more mechanisms of action likely to target and correct the underlying chemical imbalance, whereas conventional FDA-approved medications such as serotonin selective reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs) and benzodiazepines generally act through a single mechanism of action.

[0011] Due to the difficulty of tracking adverse drug reactions in combination medications, the FDA is not in the mood to approve drugs with multiple active ingredients. Therefore, a multimodal approach using only drugs is not conceivable. Nutritional and botanical supplements, which are regulated by the FDA as foods rather than drugs, can be configured as novel multicomponent administration methods and offer greater opportunities for multimodal management of anxiety. For this and other reasons, the use of natural products in humans and non-human animals is increasingly sought after as consumers seek alternatives to drugs. Currently, some of these natural products are already incorporated into dietary supplements and various foods.

[0012] As mentioned above, there is a need for natural product compositions with anxiolytic properties. The compositions should be useful in supporting normal behavior and promote sedation without inducing excessive drowsiness. Moreover, such compositions should have synergistic effects to manage and control the clinical signs or symptoms of anxiety. Summary of the Invention

[0013] In accordance with the objects and advantages described herein, one aspect of the present invention provides an anxiolytic composition comprising a synergistic combination of L-theanine and whey protein. In an embodiment, the whey protein comprises α-lactalbumin. The anxiolytic composition of the present invention induces anxiolytic changes in the release pattern of one or more neurotransmitters, including gamma-aminobutyric acid (GABA) and serotonin. The composition of the present invention can be formulated for oral administration to mammals, including humans, companion animals and equines.

[0014] In an embodiment of the invention, the synergistic composition further comprises an extract of magnolia and an extract of phellodendron.In an embodiment of the invention, the synergistic composition of the invention further comprises RELORA.

[0015] Another aspect of the invention is a method for reducing, alleviating or treating symptoms of anxiety by administering a synergistic composition comprising L-theanine and whey protein to a mammal. In an embodiment of the invention, the synergistic composition further comprises an extract of Magnolia and an extract of Phellodendron amplexicaule. In an embodiment of the invention, the whey protein is provided as a whey protein concentrate with alpha-lactalbumin. In the method of the invention, the synergistic composition is orally administered in an amount sufficient to induce anxiolytic changes in the release pattern of one or more neurotransmitters, including gamma-aminobutyric acid (GABA) and serotonin. The subject animal may be a human, canine, feline or equine.

[0016] In yet another embodiment, the anxiolytic composition comprises a synergistic composition of L-theanine and S-adenosylmethionine (SAMe) that induces anxiolytic changes in the release patterns of one or more neurotransmitters, including glutamate and gamma-aminobutyric acid (GABA).The composition can be formulated for oral administration to a mammal.In an embodiment of the invention, the SAMe comprises SAMe phytate.

[0017] In yet another aspect, the anxiolytic composition comprises a composition exhibiting synergistic effects of L-theanine, whey protein, and RELORA. In an embodiment of the invention, the whey protein comprises alpha-lactalbumin. In an embodiment of the invention, the whey protein is a whey protein concentrate.

[0018] In one embodiment of the invention, the composition of the invention has at least 2.0 mg L-theanine, at least 0.5 mg whey protein, and at least 0.5 mg RELORA. In another embodiment of the invention, the composition of the invention has at least 2.0 mg L-theanine, at least 0.5 mg whey protein, and at least 3.0 mg RELORA.

[0019] Hereinafter, some preferred embodiments of the anxiolytic composition and corresponding method of the present invention will be described. As can be understood by those skilled in the art, the composition and method of the present invention can be implemented in other different embodiments, and some details can be modified in various obvious aspects without departing from the composition and method described in the claims. Therefore, the accompanying drawings and description are illustrative in nature and are not intended to be limiting. [Brief description of the drawings]

[0020] The accompanying drawings, which are attached hereto and constitute a part of this specification, illustrate several embodiments of the anxiolytic composition of the present invention and, together with the description, serve to explain the principles of the invention. [Figure 1]FIG. 1 shows basal serotonin (5-HT) output following administration of a composition of the invention. [Diagram 2] FIG. 1 shows basal GABA output after administration of the composition of the present invention. [Diagram 3] FIG. 1 shows basal glutamate output following administration of a composition of the invention. [Figure 4] FIG. 1 shows a comparison of GABA output following administration of one embodiment of a composition of the present invention. [Diagram 5] FIG. 5 shows a comparison of glutamate output following administration of the embodiment shown in FIG. 4. [Figure 6A] FIG. 1 shows the results of an elevated plus maze (EPM) test after administration of the composition of the present invention. [Figure 6B] FIG. 1 shows a comparison of EPM tests following administration of one embodiment of the composition of the present invention. [Figure 6C] FIG. 1 shows a comparison of EPM tests following administration of another embodiment of the composition of the present invention. [Figure 7A] FIG. 1 shows the results of an open field (OF) test after administration of the composition of the present invention. [Figure 7B] FIG. 1 shows a comparison of OF tests following administration of one embodiment of the composition of the present invention. [Figure 7C] FIG. 1 shows a comparison of OF tests following administration of another embodiment of the composition of the present invention.

[0021] The anxiolytic composition of the present invention will now be described in detail with reference to the accompanying drawings, which are illustrative of the embodiments of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] The present invention relates to a composition comprising one or more of magnolia, amurella, theanine, S-adenosylmethionine (SAMe), and / or whey protein, which can be administered to humans or non-human animals. In one embodiment, the composition comprises Magnolia officinalis, Phellodendron amurense, L-theanine, and α-lactalbumin. The combination of these substances involves a number of different biochemical processes. Thus, the composition of the present invention allows for a multi-faceted approach to anxiolysis. Without being bound by theory, one potential mode is by acting on multiple neurotransmitters (such as glutamate, GABA, etc.), increasing the production of neurotransmitter levels such as serotonin, or by altering brainwave activity.

[0023] Further to the background of the present invention, Magnolia officinalis is a species of magnolia native to China. The bark and / or extract of Magnolia officinalis contains honokiol and magnolol, which enhance the activity of both synaptic and extrasynaptic GABA receptors in the brain. GABA is the brain's chief inhibitory neurotransmitter, which regulates the activity of hyperexcited neurons due to overstimulation of fear and anxiety. The action of these compounds is thought to be the selective binding to specific GABA receptors, which may explain why honokiol and magnolol exhibit anxiolytic effects without sedative effects.

[0024] Phellodendron amurense is a tree commonly known as Phellodendron amurense. The fruit, bark and / or extract of Phellodendron amurense are rich in the compound berberine. The combination of magnolia and Phellodendron amurense extract produces a synergistic effect, suppressing stress and anxiety more effectively than when used alone. Generally, synergistic effect refers to the effect of two or more ingredients used together to produce a result that is stronger than the sum of the effects when used alone. In a preferred embodiment of the present invention, the synergistic effect is stronger than an additive effect. The synergistic effect observed when magnolia and Phellodendron amurense extract are used together can be attributed to the fact that berberine inhibits the release of glutamate into the synaptic cleft by presynaptic neurons. This combination can modulate both the excitatory neurotransmitter glutamate and the inhibitory neurotransmitter GABA at the synaptic level. In a laboratory model, the combination of magnolia and Phellodendron amurense can reduce anxiety in beagles in a placebo-type clinical trial of noise-induced anxiety. In some embodiments of the invention, a commercially available formulation of a combination of Magnolia and Phellodendron amplexicaule (RELORA, InterHealth Nutraceuticals, Inc. Benicia, Canada) can be administered.

[0025] The neurotransmitters glutamate and GABA act antagonistically to regulate interactions between neurons in the brain. Glutamate is the primary excitatory neurotransmitter, making neurons more sensitive to stimulation and electrical impulses. Glutamate plays an important role in fear and anxiety, which are often the result of overstimulation. GABA is the primary inhibitory neurotransmitter in the nervous system and plays an equally important role in controlling anxiety by calming and reversing the effects of glutamate.

[0026] In one embodiment, Magnolia is combined with Phellodendron amurense extract, which shows a synergistic effect and controls stress and anxiety more effectively than either compound alone. This synergistic effect is due to the effect of these compounds on both glutamate and GABA at the synaptic level. Magnolia officinalis extract, specifically its components honokiol and magnolol, enhances the activity of both synaptic and extrasynaptic GABA receptors in the brain. Phellodendron amurense extract contains berberine, which inhibits the release of glutamate by presynaptic neurons into synaptic clefts. In other words, Magnolia extract enhances the stabilizing effect of GABA, and berberine from Phellodendron amurense extract blocks the release of excitatory glutamate.

[0027] Berberine is a bright yellow ammonium salt found in Phellodendron amurense and also in other plants such as Oregon grape, barberry, buttercup, coptis japonica and turmeric. Berberine is usually found in the roots, rhizomes, stems and bark of these plants.

[0028] L-Theanine is a structural analogue of the amino acid glutamic acid, the most important excitatory neurotransmitter in the nervous system. Found naturally in many species of tea plants, theanine is believed to exert a neuroprotective effect by binding and blocking glutamate receptors, thus inhibiting excitatory impulses and reducing the stimulatory effects of glutamic acid. Theanine increases the stability of neurotransmitters such as serotonin, dopamine and GABA in the brain. Theanine also directly stimulates the generation of alpha brain waves, creating a state of deep relaxation, wakefulness and mental alertness.

[0029] Alpha-lactalbumin is a component of certain whey protein compositions and is a high-quality protein source that provides amino acid supplementation to animals. Milk has long been considered a beverage that exhibits postprandial sedative properties, especially for infants and young animals. The first human studies on the anxiolytic effects of milk began in the 1930s and identified certain proteins in milk that have a sedative effect. Alpha-lactalbumin exerts neuroprotective properties by providing amino acid precursors for the antioxidant glutathione (cysteine) and the mood-enhancing neurotransmitter serotonin (tryptophan).

[0030] The brain consumes almost 20% of the oxygen used by the body, resulting in extremely high rates of reactive oxygen species (ROS) production, making brain cells particularly vulnerable to oxidative damage. The loss of fully developed neurons in the brain cannot be compensated for by the generation of new neurons. This leads to an imbalance between ROS production and antioxidants, which is the cause of several neurological disorders. Glutathione is the predominant antioxidant present in the nervous system. The glutathione content of brain cells is highly dependent on the availability of glutathione precursors. Alpha-lactalbumin provides cysteine, an amino acid precursor of glutathione.

[0031] Neurotransmitters are important for regulating emotional states and moods, as brain serotonin levels rise under stress.Chronic stress and anxiety can lead to insufficient available concentrations of serotonin and its precursor tryptophan, resulting in functionally inadequate serotonin levels.α-lactalbumin contains a mixture of tryptophan and other amino acids from whole food protein sources, and research suggests that dietary supplementation with α-lactalbumin enhances brain tryptophan and serotonin activity, thereby improving cognitive performance in stress-vulnerable subjects.In one embodiment of the present invention, α-lactalbumin synergizes the serotonin effects of other components of the composition, thus providing an additional mode of action.

[0032] S-adenosylmethionine (SAMe) is a naturally occurring compound present in tissues throughout the body. At the molecular level, SAMe participates in a variety of metabolic pathways, including the transmethylation, transsulfuration, and aminopropylation pathways. In the body, SAMe is synthesized from amino acids, methionine, and triphosphate nucleotides and is subsequently involved in the biosynthesis of many biological molecules, including hormones and neurotransmitters.

[0033] When administered to subjects, SAMe is known to have a variety of health-promoting effects. It regulates gene expression and helps prevent genetic mutations. SAMe also maintains mitochondrial function, participates in phospholipid synthesis, maintains cell membrane integrity, and regulates neurotransmitters such as serotonin, dopamine, and epinephrine (adrenaline), as well as hormones such as estrogen and melatonin. SAMe is also known to inhibit neuronal death after ischemia, improve glucose utilization in the brain, inhibit cerebral edema, improve EEG and evoked potential findings by normalizing them, and improve motor function, including motor function impaired by seizures. For example, in a meta-analysis of numerous drug studies, SAMe has been shown to enhance emotional well-being and to be as effective as many prescription drugs, but unlike these prescription drugs, has significantly fewer side effects. SAMe is also used to treat anxiety, chronic pain, arthritis, rheumatic fibromyalgia, chronic fatigue syndrome, cognitive difficulties associated with Alzheimer's disease, neurovascular disease, and neurological disorders associated with AIDS. SAMe can not only treat diseases of the central and peripheral nervous systems, but also improve joint, cardiovascular and liver diseases.

[0034] Initially, SAMe was considered impractical due to its ionic instability during manufacture, shipping, and storage, but eventually stable salts of SAMe were developed, including, for example, SAMe tosylate disulfate, butanedisulfonate salt of SAMe, di-para-toluene sulfonate disulfate salt of SAMe, tri-para-toluene sulfonic acid salt of SAMe, butanedisulphonate salt of SAMe, and disulfate p-toluensulfonate salt of SAMe. In an exemplary embodiment of the invention, SAMe is administered as the commercially available SAMe salt of phytic acid.

[0035] One skilled in the art would understand that the Magnolia officinalis, Phellodendron amurense, L-theanine and whey protein composition may contain any amount of each component. Each component may be in a concentrate form, such as a whey protein concentrate. Furthermore, the composition may be used in human subjects and non-human animal subjects, such as mammals, birds, fish, reptiles, etc.

[0036] In one embodiment, the composition for non-human animals may contain 0.5-3 mg of Magnolia officinalis, 0.03-0.2 mg of Phellodendron amurense, 17.0-450 mg of L-theanine, and 12.0-100 mg of α-lactalbumin. Alternatively, in another embodiment, the composition for non-human animals may contain 0.01-10 g of Magnolia officinalis, 0.01-10 g of Phellodendron amurense, 0.01 mg-10 g of L-theanine, and 0.01 mg-10 g of α-lactalbumin.

[0037] In one embodiment, the compositions of the present invention can contain at least 0.5 mg of RELORA, at least 2.0 mg of L-theanine, at least 0.5 mg of whey protein, and at least 1.5 mg of SAMe.

[0038] In one embodiment, a composition of the invention intended for non-human animals, such as canines, can contain at least 6.0 mg RELORA, at least 3.0 mg L-theanine, at least 1.0 mg whey protein, and at least 3.0 mg SAMe.

[0039] In one embodiment, a composition of the invention intended for non-human animals, such as felines, can contain at least 3.0 mg of RELORA, at least 2.0 mg of L-theanine, at least 0.5 mg of whey protein, and at least 1.0 mg of SAMe.

[0040] In one embodiment, a composition of the invention intended for non-human equine animals can contain at least 20.0 mg RELORA, at least 15.0 mg L-theanine, at least 5.0 mg whey protein, and at least 10.0 mg SAMe.

[0041] In one embodiment, a composition of the invention intended for humans can contain at least 20.0 mg RELORA, at least 15.0 mg L-theanine, at least 5.0 mg whey protein, and at least 10.0 mg SAMe.

[0042] In one embodiment intended for companion animals such as dogs and cats, the composition may contain 37 mg of RELORA, 17 mg of L-theanine, and 12 mg of whey protein per dosage form.

[0043] In one embodiment intended for companion animals such as dogs and cats, the composition may contain 75 mg of RELORA, 35 mg of L-theanine, and 25 mg of whey protein in a single dosage form.

[0044] In one embodiment intended for companion animals such as dogs and cats, the composition may contain 450 mg of RELORA, 205 mg of L-theanine, and 100 mg of whey protein in a single dosage form.

[0045] In one embodiment for pet animals such as dogs and cats, the composition may contain 0.5 mg of Magnolia officinalis extract, 0.03 mg of Phellodendron amurense extract, 17 mg of L-theanine, and 12 mg of alpha-lactalbumin per dosage form.

[0046] In one equine embodiment, the composition may contain 750 mg of RELORA, 150 mg of L-theanine, and 1000 mg of whey protein.

[0047] In one equine embodiment, the composition may contain 1500 mg of RELORA, 300 mg of L-theanine, and 1000 mg of whey protein.

[0048] Those skilled in the art will understand that the components magnolia, amplexicaule, theanine and / or whey protein (or alpha-lactalbumin) can be combined and combined in any way. For example, in one embodiment, the composition can be comprised of magnolia extract and alpha-lactalbumin, without amplexicaule or theanine. Alternatively, the composition can be comprised of amplexicaule extract and alpha-lactalbumin, without magnolia or theanine. Also, the composition can be provided with a single component of magnolia, amplexicaule, theanine and / or whey protein (or alpha-lactalbumin) that provides the desired response, or a combination with a single component of these components. The formulation can also have other flavonoids, omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), valerian, SAMe, or other milk proteins (such as alpha-S1 tryptic casein) or products containing milk proteins, and / or Sceletium tortuosum.

[0049] The compositions of the present invention can be combined in any combination and can be provided to humans or non-human animals in any combination. In one embodiment of the present invention, the compositions of the present invention have a unit dosage / administration form, suitable for example, but not limited to, oral, rectal, intravenous, transdermal, intramuscular, transdermal, transmucosal, and topical administration.

[0050] The compositions of the present invention have a dosage form that can be administered orally. Examples of dosage forms that can be administered orally include, but are not limited to, tablets, capsules, powders that can be dispersed in liquids or sprinkled on food, liquids such as solutions, suspensions and emulsions, soft gel / chew capsules, chew bars and other known dosage forms. In some embodiments of the present invention, the compositions of the present invention include tablets, capsules or soft chews. Orally administrable dosage forms can be immediate release, extended release or delayed release. The compositions of the present invention may be coated or uncoated. Example 1: Evaluation of neurotransmitter release patterns in hippocampal dialysate samples of C57B1 / 6 mice after 7 days of treatment with anxiolytic compositions

[0051] Neurotransmitter release patterns in the brain were measured by inserting (microdialysis probes) into the hypothalamic region of experimental animals and flushing the probes by dialysis with artificial cerebrospinal fluid (CSF), a commonly accepted method for obtaining and measuring in vivo brain levels of neurotransmitters and other small proteins.

[0052] The collected fluid represents the extracellular and interstitial fluids present in the hippocampus region of the brain. This is usually the preferred and common site for microdialysis, since any changes measured in this region of the brain are believed to represent approximately 80% of the total brain tissue. The neurotransmitter levels in the fluid represent not only the complex balance between the release of these neurotransmitters by presynaptic neurons and their reuptake into neurons, but also the interactions, if any, between the neurotransmitters. Thus, these results show how compounds and compound compositions affect the neurochemistry of the brain.

[0053] Female C57B1 mice were divided into groups (6 mice / group) and orally administered various compounds or a placebo for 7 days. On the 6th day, each mouse was anesthetized and a microdialysis probe was inserted into the hippocampus region of the brain. Each probe was connected to a microperfusion pump and perfused with artificial CSF, and microdialysis sampling began the day after surgery. Samples were taken in 30-minute aliquots 90 minutes before administration of each compound on the 7th day. Each aliquot was then analyzed to quantify GABA, glutamate, and serotonin (5-HT) in each sample. Neurotransmitter analysis was performed in two stages to confirm the chronic and acute effects of each compound.

[0054] In the results described below, Compound A is L-theanine, Compound B is a composition having Magnolia officinalis extract and Phellodendron amurense extract, Compound C is whey protein having α-lactalbumin, Compound D is SAMe, and Compound E is glutathione. Compound B used in the embodiment is a commercially available formulation (RELORA, InterHealth Nutraceuticals, Inc. Benicia, CA). Compound C used in the embodiment was standardized to 80% α-lactalbumin. Compound D used in the embodiment was a commercially available SAMe phytate salt. Compound A was administered at a dose of 6.66 mg / kg, Compound B at a dose of 12.5 mg / kg, Compound C at a dose of 2.36 mg / kg, Compound D at a dose of 6.02 mg / kg, and Compound E at a dose of 13.6 mg / kg. Equivalent doses for interspecies extrapolation can be calculated by those skilled in the art using routine dose conversion methods. Basal neurotransmitter output

[0055] First, measurements were taken of the basal output levels of each neurotransmitter to determine the chronic effects of each compound on neurotransmitters over time. Basal levels represent the lowest levels of each neurotransmitter in a 24-hour cycle. These levels were determined by averaging the levels of each neurotransmitter in three 30-minute aliquots prior to the 7th dosing day (sample -90 minutes to -60, sample -60 minutes to -30, and sample -30 minutes to time 0). The basal levels were measured to represent the chronic effects of the compound on neurotransmitter levels. That is, what was the minimum effect observed prior to a new dose was measured. Next, to determine the acute effects of these compounds, the levels of each neurotransmitter were analyzed in aliquots following dosing up to 3.5 hours (210 minutes) after the 7th dosing day of each compound / composition.

[0056] After six days of administration of each of the individual components of the compositions, as well as compositions having each component, the basal outputs of serotonin (5-HT), GABA, and glutamate were measured. The mean concentrations of each neurotransmitter were then compared to the mean basal outputs measured for the placebo group using a Student's test to determine whether there was a significant difference between the two sets of data.

[0057] With regard to serotonin, each of the compounds evaluated did not have a statistically significant effect (p-value < 0.05) on the basal output of serotonin (see Figure 1). That is, for example, neither L-theanine, RELORA, nor whey protein had any effect on basal serotonin levels. On the other hand, the composition of compounds A+B+C (theanine + Magnolia / Yellowfin + whey protein) had a statistically significant effect (p-value < 0.05) on the basal output of serotonin. The composition with L-theanine and whey protein (A+C) also significantly lowered basal serotonin levels. These results explain the unexpected synergistic effect of the compositions on brain serotonin levels.

[0058] An unexpected synergistic increase in GABA levels was observed for the L-theanine / Magnolia / Yellowfin (A+B) and L-theanine and whey protein (A+C) compositions (see Figure 2). Similarly, the L-theanine and SAMe (A+B) composition also significantly increased basal GABA output.

[0059] Basal glutamate output (see Figure 3) was also increased with the Theanine / Magnolia / Phenocarpus amplexicaule (A+B) composition. Similarly, the Theanine and SAMe (A+B) composition also significantly improved basal glutamate output. Acute neurotransmitter output

[0060] After the seventh dose of each compound and / or composition, CSF aliquots were collected at 30 minute increments up to 210 minutes post-dose. Neurotransmitter concentrations in each aliquot indicate acute short-term changes that were not evident in the basal output results.

[0061] The results were plotted on a graph, with the x-axis showing time after dosing on day 7 and the y-axis showing the % increase or decrease in basal power output determined in the first half of the experiment. This measurement was used because the actual concentrations of neurotransmitters varied significantly between test animals. Using this method, the data could be standardized and essentially each animal treated as its own individual control. The results were then analyzed using analysis of variance (ANOVA) to detect if there were any statistically significant treatment effects.

[0062] First, looking at the acute effects of these compounds on GABA, no statistically significant therapeutic effect was observed for each of the individual components A, B, or C when compared to placebo during the study period as analyzed by ANOVA (p<0.05), but the therapeutic effect of the composition of components (A+B+C) was statistically significantly different from placebo when analyzed by ANOVA as shown in Figure 4. Thus, these results illustrate that the composition of L-theanine and magnolia / yellowfin and whey protein (A+B+C) shows a significant synergistic effect on GABA, but each component by itself does not show any effect.

[0063] With respect to glutamate, neither the individual components (A, B, C) nor composition (A+B+C) showed a direct therapeutic effect on glutamate levels, but these results illustrate the tendency for composition (A+B+C) to exert a therapeutic effect 120-210 minutes after administration (see FIG. 5). One skilled in the art will appreciate that changes in glutamate levels are among the more difficult neurotransmitter changes to induce. Example 2: Evaluation of the anxiolytic properties of the compositions of the invention by behavioral tests

[0064] Wistar rats (16 / group) were dosed with the individual components (L-theanine, Magnolia / Yellowfin, and whey protein) and with several compositions of these three components, including a three-way composition (theanine + Magnolia / Yellowfin + whey protein). The Magnolia / Yellowfin composition was a commercial product (RELORA, InterHealth Nutraceuticals, Inc. Benicia, Canada). The whey protein administered was standardized to 80% alpha-lactalbumin. Rats were dosed daily for 14 days, and then a series of behavioral assessments were performed to detect whether the rats had an anxiolytic or sedative effect. Treatment groups were as follows: 1: L-theanine + Magnolia / Yellowfin 2: L-theanine + whey protein 3: Magnolia / Yellowfin + Whey Protein 4: L-theanine + Magnolia / Yellowfin + Whey Protein 5: L-theanine 6: Magnolia / Yellowfin 7: Whey protein The rats were divided into the following groups: TIFF2024160292000002.tif72163 Elevated plus maze test

[0065] The elevated plus maze (EPM) test exploits rodents' natural aversion (trait anxiety) to brightly lit, open, elevated areas. The EPM is highly predictive and is often used to elucidate the potential anxiolytic activity of compounds. During this test, rats are videotaped after being placed in the elevated maze. The video images are analyzed to determine the % of time the rats spend in the open, elevated portion of the maze. Rats that spend more time in the open arms are considered to feel less anxiety. Table 1 below shows the average amount of time each rat spent in the open arms of the maze. Table 1 TIFF2024160292000003.tif51105

[0066] In this experiment, rats administered the composition with ingredients from Treatment 4 stayed in the open arms of the maze for an average of 3 minutes longer than rats administered placebo (see FIG. 6A), demonstrating the anxiolytic effects of the compound. Similarly, rats administered the composition with L-theanine / whey protein (Treatment 2) stayed in the open arms of the maze for an average of 5 minutes longer than rats administered placebo (see FIG. 6), demonstrating the anxiolytic effects of the compound. The L-theanine / magnolia / yellowfin tuna composition (Treatment 1) and the magnolia / yellowfin tuna / whey protein composition (Treatment 3) showed statistically significant effects in post-hoc contrasts (both analyzed at p<0.05; see FIG. 6B and FIG. 6C, respectively). Open field activity as a measure of sedation

[0067] Locomotor activity in the open field test is a good measure of the sedative properties of a compound. As an example, a prominent side effect of many anxiolytic compounds, such as benzodiazepines, is the significant sedative effects associated with their administration. Although these substances are fairly effective anxiolytics, they often have undesirable sedative effects.

[0068] The test involves placing rats in a brightly lit enclosure with free access. The rats are videotaped and the total distance traveled by the rat during the test is recorded as a measure of locomotor activity. Sedated rats travel shorter distances, while active rats travel greater total distances. Table 2 TIFF2024160292000004.tif51105a: One rat was excluded from analysis due to inaccurate video tracking.

[0069] The results, listed in Table 2 and illustrated in Figure 7A, show that none of the administered compounds / compositions had a sedative effect on the locomotor activity of the rats. All rats were more active than placebo and showed avid interest in exploring and exploring. In fact, post-hoc contrasts showed a trend towards higher locomotor activity, especially for treatment 1 [t(30)=3.58, p<0.01; t-test] and treatment 3 [t(30)=1.99, p<0.06; t-test] (see Figures 7B and 7C). Compounds that have anxiolytic effects without sedating effects are considered highly desirable candidates for treating anxiety.

[0070] From the above results, it can be seen that a composition suitable for oral administration and effective in various embodiments can be provided, which can affect brain neurochemistry, as shown by the ability to induce changes in the release patterns of various neurotransmitters. Moreover, various behavioral assessments demonstrate the anxiolytic effect of various compositions of the present invention. Although the individual compounds of the compositions of the present invention do not have an effect on brain neurochemistry or behavior, surprisingly, the compositions have a synergistic effect.

[0071] The above description is intended to be illustrative and not exhaustive, and in other words, is not intended to limit the embodiments to the precise form disclosed. Obvious modifications and variations are possible in light of the above disclosure. The above embodiments have been selected to provide the best possible implementation for the specific intended use, enabling one skilled in the art to implement the invention in various embodiments. These modifications and variations are intended to be encompassed within the scope of the appended claims when interpreted in accordance with their fair, legal, and equitable scope.

Claims

1. 1. An anxiolytic composition comprising whey protein and an extract of Magnolia and an extract of Phellodendron amplexicaule for administration to a mammal in need thereof.

2. The composition of claim 1, wherein the whey protein comprises alpha-lactalbumin.

3. The composition of claim 1 or 2, wherein the composition induces anxiolytic effects without sedation.

4. 4. The composition of claim 3, wherein said mammal is selected from the group consisting of humans, pet animals, and equines.

5. 1. A method for suppressing, alleviating or treating a symptom of anxiety comprising administering to a non-human mammal in need thereof a composition comprising whey protein and an extract of Magnolia and an extract of Phellodendron amplexicaule to suppress, alleviate or treat a symptom of anxiety.

6. The method of claim 5, wherein the whey protein comprises alpha-lactalbumin.

7. 7. The method of claim 5 or 6, wherein the composition induces anxiolytic effects without sedation.

8. 8. The method of claim 7, wherein said mammal is selected from the group consisting of humans, companion animals, and equines.

Citation Information

Patent Citations

  • A mixture of peptide-bound tryptophan and polypeptide-bound tryptophan.

    JP2011523547A